A Phase 1 trial evaluating AB-836 in healthy volunteers
Latest Information Update: 16 Aug 2022
At a glance
- Drugs AB-836 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
Most Recent Events
- 04 Aug 2022 According to an Arbutus media release, company will provide an update with respect to the status and timing of this clinical trial in the second half of 2022.
- 01 Jul 2022 New trial record